Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis
Primary Purpose
Heart Failure
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Entresto
Sponsored by
About this trial
This is an interventional treatment trial for Heart Failure
Eligibility Criteria
Inclusion Criteria:
- Males and females aged ≥18 years
Congestive Heart Failure (CHF) New York Heart Association (NYHA) class II-IV with 25%≤ Left Ventricular Ejection Fraction (LVEF) ≤40% (ECHO within last 6 months)
- NT-proBNP ≥ 600 pg/mL OR
- NT-proBNP ≥ 400 pg/mL and a hospitalization for heart failure within the last 12 months
- Stable and optimized on an angiotensin-converting-enzyme inhibitor (ACEI) equivalent to enalapril ≥ 10 twice a day (BID) for at least 4 weeks
- Stable and optimized on a beta-blocker for at least 4 weeks
- Optimized dosing of aldosterone antagonist at stable dose for at least 4 weeks
Exclusion Criteria:
- History of angioedema
- estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2 at screening
- Serum potassium > 5.2 mmol/L at screening
- Symptomatic hypotension as defined by Investigator, systolic blood pressure (SBP) < 100 mmHg at screening
- Current acute decompensated heart failure
- History of severe pulmonary disease
- Active malignancy
- Requirement for treatment with both angiotensin-converting-enzyme inhibitor (ACEI) and angiotensin receptor blockers (ARB)
Sites / Locations
- University of Chicago Medical Center
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Open label Entresto
Arm Description
All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.
Outcomes
Primary Outcome Measures
Change From Baseline in LV Remodeling 2D End-Diastolic Diameter (cm)
LV Remodeling 2D End-Diastolic Diameter (cm)
Change From Baseline in LV Remodeling 2D End-Systolic Diameter (cm)
LV Remodeling 2D End-Systolic Diameter (cm)
Change From Baseline in LV Remodeling Global Longitudinal Strain (%)
LV Remodeling Global Longitudinal Strain (%)
Change From Baseline in LV Remodeling Left Atrial Volume (mL)
LV Remodeling Left Atrial Volume (mL)
Change From Baseline in LV Remodeling 3D End-Diastolic Volume (mL)
LV Remodeling 3D End-Diastolic Volume (mL)
Change From Baseline in LV Remodeling 3D End-Systolic Volume (mL)
LV Remodeling 3D End-Systolic Volume (mL)
Change From Baseline in LV Remodeling LV Ejection Fraction (%)
LV Remodeling LV Ejection Fraction (%)
Change From Baseline in LV Remodeling Conicity (%)
LV Remodeling Conicity (%)
Change From Baseline in LV Remodeling Sphericity (%)
LV Remodeling Sphericity (%)
Change From Baseline in RV Remodeling End-Diastolic Volume (mL)
RV Remodeling End-Diastolic Volume (mL)
Change From Baseline in RV Remodeling End Systolic Volume (mL)
RV Remodeling End Systolic Volume (mL)
Change From Baseline in RV Remodeling Ejection Fraction (%)
RV Remodeling Ejection Fraction (%)
Change From Baseline in RV Remodeling Septal Curvature (%)
RV Remodeling Septal Curvature (%)
Change From Baseline in RV Remodeling Free-Wall Curvature (%)
RV Remodeling Free-Wall Curvature (%)
Change From Baseline in RV Remodeling Tricuspid Regurgitation
RV Remodeling Tricuspid Regurgitation
Secondary Outcome Measures
Change From Baseline in Rho-associated Protein Kinase (ROCK)
Rho-associated protein kinase (ROCK)
Change From Baseline in (MIBG) Early hm Ratio
Cardiac 123Iodine-metaiodobenzylguanidine (MIBG) Early heart/mediastinum ratio (hm) ratio
Change From Baseline in (MIBG) Late hm Ratio
Cardiac 123Iodine-metaiodobenzylguanidine (MIBG) Late heart/mediastinum ratio (hm) ratio
Change From Baseline in NT-proBNP Levels
NT-proBNP levels (pg/ml)
Change From Baseline in Exercise Performance - 6 Minute Walk
Exercise Performance - 6 Minute Walk
Change From Baseline in Exercise Performance - CPX - Peak VO2 (mL/kg/Min)
Exercise Performance - CPX - Peak VO2 (mL/kg/min)
Change From Baseline in Exercise Performance - CPX - Peak RER
Exercise Performance - CPX - Peak RER (Respiratory Exchange Ratio)
Change From Baseline in Exercise Performance - CPX - VE/VC02
Exercise Performance - CPX - VE/VC02
Change From Baseline in Blood Pressure - Systolic (mmHg)
Blood Pressure - Systolic (mmHg)
Change From Baseline in Blood Pressure - Diastolic (mmHg)
Blood Pressure - Diastolic (mmHg)
Change From Baseline in KCCQ - Physical Limitation
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Change From Baseline in KCCQ - Symptom Stability
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Change From Baseline in KCCQ - Symptom Frequency
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Change From Baseline in KCCQ - Symptom Burden
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Change From Baseline in KCCQ - Total Symptom
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Change From Baseline in KCCQ - Self Efficacy
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Change From Baseline in KCCQ - Quality of Life Score
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Change From Baseline in KCCQ - Social Limitation
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Change From Baseline in KCCQ - Overall Summary
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Change From Baseline in KCCQ - Clinical Summary
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02754518
Brief Title
Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis
Official Title
Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
April 2019 (Actual)
Study Completion Date
April 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Chicago
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study intends to measure the effects of valsartan/sacubitril compared to baseline standard medical heart failure therapy on reverse remodeling using echocardiographic endocardial surface analysis techniques to assess changes in ventricular volume, function, and shape.
Detailed Description
This study intends to measure the effects of valsartan/sacubitril compared to baseline standard medical heart failure therapy on reverse remodeling using echocardiographic endocardial surface analysis techniques to assess changes in ventricular volume, function, and shape. Furthermore, Metaiodobenzylguanidine (MIBG) scintigraphy and the heart to mediastinum ratio will be used to assess Left Ventricle (LV) volume regression and risk reduction. The investigators also intend to measure the effects of valsartan/sacubitril on exercise capacity as assessed by the 6 minute walk test and peak Volume of Oxygen (V02) on cardiopulmonary exercise testing. Additionally, the investigators will examine the impact of valsartan/sacubitril on functional status and quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and Qualia Health (a novel iPhone application that incorporates Fitbit technology to provide a "real time" daily 6 minute step count and assesses quality of life using a series of short targeted questions. The investigators will also measure Brain Natriuretic Peptide (BNP), N-terminal of the Prohormone Brain Natriuretic Peptide (NT-proBNP), and Rho-kinase (a biomarker associated with heart failure) levels at multiple time-points throughout the study period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Open label Entresto
Arm Type
Other
Arm Description
All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.
Intervention Type
Drug
Intervention Name(s)
Entresto
Other Intervention Name(s)
valsartan/sacubitril
Primary Outcome Measure Information:
Title
Change From Baseline in LV Remodeling 2D End-Diastolic Diameter (cm)
Description
LV Remodeling 2D End-Diastolic Diameter (cm)
Time Frame
Baseline,1 year
Title
Change From Baseline in LV Remodeling 2D End-Systolic Diameter (cm)
Description
LV Remodeling 2D End-Systolic Diameter (cm)
Time Frame
Baseline,1 year
Title
Change From Baseline in LV Remodeling Global Longitudinal Strain (%)
Description
LV Remodeling Global Longitudinal Strain (%)
Time Frame
Baseline,1 year
Title
Change From Baseline in LV Remodeling Left Atrial Volume (mL)
Description
LV Remodeling Left Atrial Volume (mL)
Time Frame
Baseline,1 year
Title
Change From Baseline in LV Remodeling 3D End-Diastolic Volume (mL)
Description
LV Remodeling 3D End-Diastolic Volume (mL)
Time Frame
Baseline,1 year
Title
Change From Baseline in LV Remodeling 3D End-Systolic Volume (mL)
Description
LV Remodeling 3D End-Systolic Volume (mL)
Time Frame
Baseline,1 year
Title
Change From Baseline in LV Remodeling LV Ejection Fraction (%)
Description
LV Remodeling LV Ejection Fraction (%)
Time Frame
Baseline,1 year
Title
Change From Baseline in LV Remodeling Conicity (%)
Description
LV Remodeling Conicity (%)
Time Frame
Baseline,1 year
Title
Change From Baseline in LV Remodeling Sphericity (%)
Description
LV Remodeling Sphericity (%)
Time Frame
Baseline,1 year
Title
Change From Baseline in RV Remodeling End-Diastolic Volume (mL)
Description
RV Remodeling End-Diastolic Volume (mL)
Time Frame
Baseline,1 year
Title
Change From Baseline in RV Remodeling End Systolic Volume (mL)
Description
RV Remodeling End Systolic Volume (mL)
Time Frame
Baseline,1 year
Title
Change From Baseline in RV Remodeling Ejection Fraction (%)
Description
RV Remodeling Ejection Fraction (%)
Time Frame
Baseline,1 year
Title
Change From Baseline in RV Remodeling Septal Curvature (%)
Description
RV Remodeling Septal Curvature (%)
Time Frame
Baseline,1 year
Title
Change From Baseline in RV Remodeling Free-Wall Curvature (%)
Description
RV Remodeling Free-Wall Curvature (%)
Time Frame
Baseline,1 year
Title
Change From Baseline in RV Remodeling Tricuspid Regurgitation
Description
RV Remodeling Tricuspid Regurgitation
Time Frame
Baseline,1 year
Secondary Outcome Measure Information:
Title
Change From Baseline in Rho-associated Protein Kinase (ROCK)
Description
Rho-associated protein kinase (ROCK)
Time Frame
Baseline,1 year
Title
Change From Baseline in (MIBG) Early hm Ratio
Description
Cardiac 123Iodine-metaiodobenzylguanidine (MIBG) Early heart/mediastinum ratio (hm) ratio
Time Frame
Baseline,1 year
Title
Change From Baseline in (MIBG) Late hm Ratio
Description
Cardiac 123Iodine-metaiodobenzylguanidine (MIBG) Late heart/mediastinum ratio (hm) ratio
Time Frame
Baseline,1 year
Title
Change From Baseline in NT-proBNP Levels
Description
NT-proBNP levels (pg/ml)
Time Frame
Baseline,1 year
Title
Change From Baseline in Exercise Performance - 6 Minute Walk
Description
Exercise Performance - 6 Minute Walk
Time Frame
Baseline,1 year
Title
Change From Baseline in Exercise Performance - CPX - Peak VO2 (mL/kg/Min)
Description
Exercise Performance - CPX - Peak VO2 (mL/kg/min)
Time Frame
Baseline,1 year
Title
Change From Baseline in Exercise Performance - CPX - Peak RER
Description
Exercise Performance - CPX - Peak RER (Respiratory Exchange Ratio)
Time Frame
Baseline,1 year
Title
Change From Baseline in Exercise Performance - CPX - VE/VC02
Description
Exercise Performance - CPX - VE/VC02
Time Frame
Baseline,1 year
Title
Change From Baseline in Blood Pressure - Systolic (mmHg)
Description
Blood Pressure - Systolic (mmHg)
Time Frame
Baseline,1 year
Title
Change From Baseline in Blood Pressure - Diastolic (mmHg)
Description
Blood Pressure - Diastolic (mmHg)
Time Frame
Baseline,1 year
Title
Change From Baseline in KCCQ - Physical Limitation
Description
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Time Frame
Baseline,1 year
Title
Change From Baseline in KCCQ - Symptom Stability
Description
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Time Frame
Baseline,1 year
Title
Change From Baseline in KCCQ - Symptom Frequency
Description
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Time Frame
Baseline,1 year
Title
Change From Baseline in KCCQ - Symptom Burden
Description
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Time Frame
Baseline,1 year
Title
Change From Baseline in KCCQ - Total Symptom
Description
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Time Frame
Baseline,1 year
Title
Change From Baseline in KCCQ - Self Efficacy
Description
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Time Frame
Baseline,1 year
Title
Change From Baseline in KCCQ - Quality of Life Score
Description
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Time Frame
Baseline,1 year
Title
Change From Baseline in KCCQ - Social Limitation
Description
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Time Frame
Baseline,1 year
Title
Change From Baseline in KCCQ - Overall Summary
Description
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Time Frame
Baseline,1 year
Title
Change From Baseline in KCCQ - Clinical Summary
Description
KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.
Time Frame
Baseline,1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males and females aged ≥18 years
Congestive Heart Failure (CHF) New York Heart Association (NYHA) class II-IV with 25%≤ Left Ventricular Ejection Fraction (LVEF) ≤40% (ECHO within last 6 months)
NT-proBNP ≥ 600 pg/mL OR
NT-proBNP ≥ 400 pg/mL and a hospitalization for heart failure within the last 12 months
Stable and optimized on an angiotensin-converting-enzyme inhibitor (ACEI) equivalent to enalapril ≥ 10 twice a day (BID) for at least 4 weeks
Stable and optimized on a beta-blocker for at least 4 weeks
Optimized dosing of aldosterone antagonist at stable dose for at least 4 weeks
Exclusion Criteria:
History of angioedema
estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2 at screening
Serum potassium > 5.2 mmol/L at screening
Symptomatic hypotension as defined by Investigator, systolic blood pressure (SBP) < 100 mmHg at screening
Current acute decompensated heart failure
History of severe pulmonary disease
Active malignancy
Requirement for treatment with both angiotensin-converting-enzyme inhibitor (ACEI) and angiotensin receptor blockers (ARB)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sara Kalantari, MD
Organizational Affiliation
University of Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Chicago Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis
We'll reach out to this number within 24 hrs